NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee D meeting minutes

**Minutes:** Confirmed

**Date and time:** Thursday 7 July 2022

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Megan John (Chair) Present for all items
2. Dr Lindsay Smith (Vice Chair) Present for all items
3. Martin Bradley Present for all items
4. Dr Matthew Bradley Present for all items
5. Professor Sofia Dias Present for all items
6. Chris Herring Present for all items
7. Dr Andrew Hitchings Present for all items
8. Dr Robert Hodgson Present for all items
9. Dr Bernard Khoo Present for all items
10. Ivan Koychev Items 1 to 4.2.2
11. Dr Soo Fon Lim Present for all items
12. Dr Guy Makin Present for all items
13. Dr Philip Mallender Present for all items
14. Professor David Meads Present for all items
15. Giles Monnickendam Present for all items
16. Dr Malcolm Oswald Present for all items
17. Professor Chris Parker Items 1 to 4.2.2
18. Dr Rebecca Payne Present for all items
19. Carole Pitkeathley Present for all items
20. Professor Athanasos Saratzis Present for all items
21. Professor John Watkins Present for all items

NICE staff present

Helen Knight, Programme Director Items 6 to 6.2.2

Linda Landells, Associate Director Items 1 to 4.2.2

Jasdeep Hayre, Associate Director Items 5 to 6.2.2

Kate Moore, Project Manager Items 1 to 4.2.2

Celia Mayers, Project Manager Items 5 to 6.2.2

Lorna Dunning, Heath Technology Assessment Adviser Items 1 to 4.2.2

Sally Doss, Heath Technology Assessment Adviser Items 5 to 5.2.2

Michelle Green, Heath Technology Assessment Adviser Items 6 to 6.2.2

Catherine Parker, Heath Technology Assessment Analyst Items 1 to 4.2.2

Ziqi Zhou, Heath Technology Assessment Analyst Items 5 to 5.2.2

Lizzie Walker, Heath Technology Assessment Analyst Items 6 to 6.2.2

Ross Wilkinson, Heath Technology Assessment Analyst Items 6 to 6.2.2

Catherine Spanswick, Heath Technology Assessment Analyst Items 6 to 6.2.2

Maroulla Whiteley, Business Analyst, RIA Present for all items

James Baker, Media Relations Executive Items 5 to 5.2.2

Catrin Austin, Technical Analyst, Methods, and Economics Items 5 to 6.2.2

Emily Eaton-Turner, Technical Analyst, Commercial Risk Assessment Items 5 to 6.2.2

Neha Jiandani, Technical Analyst, Commercial Liaison Items 5 to 6.2.2

Ella Livingstone, Technical Analyst, Commercial Risk Assessment Items 5 to 6.2.2

Helen Barnett, Senior Medical Editor Items 1 to 4.2.2

Hayley Garnett, Senior Medical Editor Items 5 to 5.2.2

Laura Marsden, Public Involvement Adviser, PIP Items 5 to 5.1.2

Catherine Pank, Assistant Project Manager Present for all items

Rosalee Mason, Coordinator, MIP Items 1 to 4.1.3 & 5 to 5.1.3

Mohammed Towhasir, Administrator, TA Items 1 to 4.2.2

Leah Kelly, Administrator, TA Items 5 to 5.2.2

Laura Kelly, Administrator, COT Items 6 to 6.2.2

External assessment group representatives present

Robert Wolff, Kleijnen Systematic Reviews Ltd (KSR), Items 1 to 4.1.3

Maiwenn Al, Kleijnen Systematic Reviews Ltd (KSR), Items 1 to 4.1.3

Maxwell Barnish, Peninsula Technology Assessment Group (Pen-TAG), Items 5 to 5.1.3

Will Sullivan, Peninsula Technology Assessment Group (Pen-TAG), Items 5 to 5.1.3

Katherine Edwards, Liverpool Reviews, and Implementation Group (LRIG), Items 6 to 6.1.3

Sophie Beale, Liverpool Reviews, and Implementation Group (LRIG), Items 6 to 6.1.3

Clinical, Patient & NHS England experts present

Dr Sanjeev Patel, Innovative Medicines Fund Clinical lead, NHS England, Items 1 to 4.2.2

Professor Peter Clark, Cancer Drug Fund Clinical Lead, NHS England, Items 5 to 6.2.2

Prof. Sanjay Popat, Consultant Medical Oncologist & Professor of Thoracic Oncology, Clinical expert nominated by EQRx, Items 6 to 6.1.3

Dr Yvonne Summers, Consultant Medical Oncologist, Clinical expert nominated by AstraZeneca, Items 6 to 6.1.3

Angela Terry, Patient expert nominated by EGFR Positive UK, Items 6 to 6.1.3

## Minutes

### Introduction to the meeting

* 1. The chair Dr Megan John welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted apologies from committee members.

### News and announcements

* 1. The chair welcomed new committee members Professor Athanasios Saratzis and Dr Philip Mallender as observers

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Thursday 26 June 2022.

### Appraisal of avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis [ID1581]

* 1. Part 1 – Open session
     1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Vifor Pharma
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* There were no interests declared for this appraisal.
  + 1. The Chair led a discussion of the consultation comments presented to the committee.
  1. Part 2 – Closed session (company representatives, external assessment group representatives and members of the public were asked to leave the meeting).
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10740>

### Appraisal of atezolizumab for adjuvant treatment of resected non-small-cell lung cancer [ID3852]

* 1. Part 1 – Open session
     1. The chair Dr Lindsay Smith welcomed the invited expert, external assessment group representatives, members of the public and company representatives from Roche
     2. The chair asked all committee members and expert, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Dr Matt Bradley declared financial interests as he holds shares in AstraZeneca, the manufacturer of an identified and participating comparator (Osimertinib). As a direct conflict it was agreed that Dr Bradley would not participate in discussions of this appraisal.
* No further interests were declared for this appraisal.
  + 1. The Chair led a discussion of the consultation comments presented to the committee.
  1. Part 2 – Closed session (company representatives, external assessment group representatives and members of the public were asked to leave the meeting).
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10751>

### Appraisal of aumolertinib for untreated EGFR mutation-positive non-small-cell lung cancer [ID4000]

The Medicine and Healthcare products Regulatory Agency (MHRA) have not yet given their regulatory opinion for aumolertinib for untreated EGFR mutation-positive non-small-cell lung cancer and therefore this discussion will take place in a part 2 session (part 2 sessions are closed to public observers).

* 1. Part 2a – Closed session
     1. The chair Dr Megan John welcomed the invited experts, external assessment group representatives and company representatives from EQRx.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Dr Matt Bradley declared financial interests as he holds shares in AstraZeneca, the manufacturer of an identified and participating comparator (Osimertinib). As a direct conflict it was agreed that Dr Bradley would not participate in discussions of this appraisal.
* Nominated clinical expert Professor Sanjay Popat declared direct financial and indirect interests as he
  + - * Has received consultancy & honoraria fees from Amgen, AstraZeneca, Bayer, BeiGene, Blueprint, BMS, Boehringer Ingelheim, Daiichi Sankyo, GSK, Guardant Health, Incyte, Janssen, Lilly, Merck KGaA, MSD, Novartis, Roche, Takeda, Pfizer, Seattle Genetics, Turning Point Therapeutics, Xcovery
      * He is advisor for ALK Positive UK, Lung Cancer Europe, Ruth Strauss Foundation (non-reimbursed) Foundation (non-reimbursed)
      * He is on the board of directors for Mesothelioma Applied Research
      * He is committee chair of BTOG Steering and Council Member for ETOP IBSCG Partners Foundation (non-reimbursed).
* It was agreed his declaration did not prevent Professor Popat from providing expert advice to the committee.
* Nominated clinical expert Dr Yvonne Summers declared direct financial interests as she has received paid advisory board and educational activities for AstraZeneca. It was agreed her declaration would not prevent Dr Summers from providing expert advice to the committee.
* No further interests were declared for this appraisal.
  + 1. The Chair led a discussion of the consultation comments presented to the committee.
  1. Part 2b – Closed session (company representatives, patient and clinical experts and external assessment group representatives were asked to leave the meeting).
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached through a vote by members.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10751>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee D will be held on Thursday 4 August 2022 and will start promptly at 9:30am.